<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82245">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836848</url>
  </required_header>
  <id_info>
    <org_study_id>NCH-NIRS-001</org_study_id>
    <nct_id>NCT01836848</nct_id>
  </id_info>
  <brief_title>Non-invasive Measuring of Cerebral Perfusion After Severe Brain Injury With Near-infrared-spectroscopy and ICG</brief_title>
  <official_title>Continuous, Non-invasive Monitoring of Cerebral Oxygenation and Perfusion Using Near-infrared Spectroscopy With Indocyanine Green Perfusion Measurement in Patients With Traumatic Brain Injury, Intracerebral or Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne, Departement General Neurosurgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show if it is possible to detect secondary ischemic events
      in patients with severe brain injury or cerebral haemorrhage with the help of non-invasive
      near-infrared spectroscopy (NIRS) by using the indocyanine green measuring of cerebral
      perfusion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>with near-infrared-spectroscopy detected cerebral perfusion deficit</measure>
    <time_frame>15 days after ictus</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determining a threshold value for cerebral autoregulation measured with near-infrared-spectroscopy as a predictive value for the clinical outcome</measure>
    <time_frame>15 days after ictus and follow up 6 month later</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Intracerebral Hemorrhage (ICH)</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>indocyanine green</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>measuring cerebral perfusion by NIRS with ICG</intervention_name>
    <description>application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)</description>
    <arm_group_label>indocyanine green</arm_group_label>
    <other_name>indocyanine green</other_name>
    <other_name>NIRO-200NX C10488, Hamamatsu Photonics K.K.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years

          -  onset of clinical symptoms of subarachnoid or intracranial haemorrhage or trauma
             suffered less than 72h

          -  indication for implanting a tissue oxygen and intracranial pressure probe

          -  A signed informed consent by the patient or legal guardian

        Exclusion Criteria:

          -  Persistent epidural, subdural or subcutaneous hematoma in planned area of

               -  the NIRS optode

          -  Open injuries in the area of the planned optodes

          -  Malignant primary disease under chemotherapy

          -  pregnancy

          -  bleeding disorder

          -  In the short term unfavorable prognosis (eg, bilateral wide and light-fixed pupils)

          -  Patients with pacemakers or where no MRI compatibility is due to non- removable metal
             parts

          -  contraindications for contrast media in CT (eg, iodine allergy)

          -  Untreated hyperthyroidism

          -  End Stage Renal Disease

          -  severe psychomotor agitation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerrit Brinker, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitiy of Cologne, Departement of General Neurosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of General Neurosurgery of th University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André Pascal Schulte, physician</last_name>
      <phone>0049 (0)221 478 97707</phone>
      <email>andre.schulte@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Reiner, physician</last_name>
      <phone>0049 (0)221 478 97710</phone>
      <email>michael.reiner@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Reiner, physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>André Pascal Schulte, physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerrit Brinker, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 17, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Gerrit Brinker</investigator_full_name>
    <investigator_title>senior physician</investigator_title>
  </responsible_party>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>near-infrared-spectroscopy</keyword>
  <keyword>indocyanine green</keyword>
  <keyword>secondary ischemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
